乌司奴单克隆抗体（UST）和维得利珠单克隆抗体（VDZ）在中国已经上市1年余，初始对药物治疗应答的患者在后续继续治疗的过程中均可能存在失应答的情况，如何进行有效、规范的针对性处理成为临床工作者面临的重要问题。由于这两种药物的作用机制、剂型、使用方法及免疫原性均与既往药物不尽相同，故针对其失应答的应对策略也应作出改变。本文结合近年来国内外发表的与UST及VDZ相关的循证医学证据来探讨这两种新型生物制剂失应答的发生情况及应对策略。“,”Ustekinumab (UST) and vedolizumab (VDZ) have been marketed in China for more than a year. Patients who initially respond to these drugs may experience loss of response (LOR) during subsequent treatment. How to carry out effective and standardized targeted treatment of LOR has become an important problem faced by clinicians. Since the mechanism of action, dosage form, method of use and immunogenicity of the two drugs are different from the previous biologics, the coping strategies for their LOR should also be changed accordingly. This article combines the evidence-based medical evidence related to UST and VDZ published in recent years to discuss the prevalence and coping strategies of LOR to the two new biologics.